DK0870044T3 - Reguleret proteinekspression i stabilt transfekterede pattedyrsceller - Google Patents

Reguleret proteinekspression i stabilt transfekterede pattedyrsceller

Info

Publication number
DK0870044T3
DK0870044T3 DK96940158T DK96940158T DK0870044T3 DK 0870044 T3 DK0870044 T3 DK 0870044T3 DK 96940158 T DK96940158 T DK 96940158T DK 96940158 T DK96940158 T DK 96940158T DK 0870044 T3 DK0870044 T3 DK 0870044T3
Authority
DK
Denmark
Prior art keywords
pct
gene therapy
parvovirus
expression
date jun
Prior art date
Application number
DK96940158T
Other languages
English (en)
Inventor
Markus Peter Wilhelm Einerhand
Domenico Valerio
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of DK0870044T3 publication Critical patent/DK0870044T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96940158T 1995-12-01 1996-11-29 Reguleret proteinekspression i stabilt transfekterede pattedyrsceller DK0870044T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95203307 1995-12-01
PCT/NL1996/000472 WO1997020943A1 (en) 1995-12-01 1996-11-29 Regulated protein expression in stably transfected mammalian cells

Publications (1)

Publication Number Publication Date
DK0870044T3 true DK0870044T3 (da) 2004-08-02

Family

ID=8220893

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96940158T DK0870044T3 (da) 1995-12-01 1996-11-29 Reguleret proteinekspression i stabilt transfekterede pattedyrsceller

Country Status (9)

Country Link
US (1) US6140103A (da)
EP (1) EP0870044B1 (da)
JP (1) JP3881382B2 (da)
AT (1) ATE264398T1 (da)
AU (1) AU7710996A (da)
DE (1) DE69632201T2 (da)
DK (1) DK0870044T3 (da)
ES (1) ES2219700T3 (da)
WO (1) WO1997020943A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160406A0 (en) * 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
AU1576501A (en) * 1999-10-28 2001-05-08 Research Development Foundation Methods to enhance and confine gene expression in cancer therapy
MX359371B (es) * 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
EP2543734A1 (en) * 2011-07-07 2013-01-09 Deutsches Krebsforschungszentrum Adeno-parvovirus chimera with enhanced oncolytical potential
EP3456822A1 (en) * 2017-09-19 2019-03-20 CEVEC Pharmaceuticals GmbH Inducible aav rep genes
GB201800903D0 (en) 2018-01-19 2018-03-07 Oxford Genetics Ltd Vectors
GB201901571D0 (en) * 2019-02-05 2019-03-27 Oxford Genetics Ltd Inducible AAV sysyem

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
WO1995013365A1 (en) * 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US5851796A (en) * 1995-06-07 1998-12-22 Yale University Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes
IL160406A0 (en) * 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products

Also Published As

Publication number Publication date
ES2219700T3 (es) 2004-12-01
EP0870044B1 (en) 2004-04-14
DE69632201T2 (de) 2005-04-21
JP2000501934A (ja) 2000-02-22
ATE264398T1 (de) 2004-04-15
DE69632201D1 (de) 2004-05-19
EP0870044A1 (en) 1998-10-14
AU7710996A (en) 1997-06-27
JP3881382B2 (ja) 2007-02-14
WO1997020943A1 (en) 1997-06-12
US6140103A (en) 2000-10-31

Similar Documents

Publication Publication Date Title
Berdien et al. TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer
US11674128B2 (en) Engineering of a minimal SaCas9 CRISPR/Cas system for gene editing and transcriptional regulation optimized by enhanced guide RNA
US6207453B1 (en) Recombinant AAV vector-based transduction system and use of same
Li et al. Muscle-specific enhancement of gene expression by incorporation of SV40 enhancer in the expression plasmid
Diaz et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy
Bros et al. The human fascin gene promoter is highly active in mature dendritic cells due to a stage-specific enhancer
Ferreira et al. Optimization of a gene electrotransfer method for mesenchymal stem cell transfection
Alexander et al. Transfer of contaminants in adeno-associated virus vector stocks can mimic transduction and lead to artifactual results
PT728214E (pt) Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
DE69535703D1 (de) Aav-vermittelte überbringung von dna in zellen des nervensystems
DE69824859D1 (de) Methoden zur erhöhung der effizienz rekombinanter aav produkte
AU7599500A (en) Novel gl50 molecules and uses therefor
ATE236263T1 (de) Adeno-assozierter virus 2 basalvektoren
Pochampally et al. Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects
Alaee et al. Suicide gene approach using a dual-expression lentiviral vector to enhance the safety of ex vivo gene therapy for bone repair
Fenjves Approaches to gene transfer in keratinocytes
DK0870044T3 (da) Reguleret proteinekspression i stabilt transfekterede pattedyrsceller
PT988391E (pt) Vectores adenovirais recombinantes compreendendo uma sequencia de splicing
Zuo et al. Actin binding activity of subunit B of vacuolar H+‐ATPase is involved in its targeting to ruffled membranes of osteoclasts
Cao et al. Muscle stem cells can act as antigen-presenting cells: implication for gene therapy
Fehse et al. Highly‐efficient gene transfer with retroviral vectors into human T lymphocytes on fibronectin
Wang et al. Shortened nuclear matrix attachment regions are sufficient for replication and maintenance of episomes in mammalian cells
Gagnoux‐Palacios et al. Assessment of optimal transduction of primary human skin keratinocytes by viral vectors
Nettelbeck et al. A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control
Wright Gene therapy for the eye